Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside

Biochemical Pharmacology

Volumn 67, Issue 9, 2004, Pages 1639-1646

  Masquelier, Michèle ^a   Vitols, Sigurd ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; ALL; AML; AraC; Cell count; Cytarabine (AraC); Cytosine arabinoside; Daunorubicin; Daunorubicin (DNR); DNR; WBC; White blood cell count

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL COUNT; CELL DENSITY; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL COUNT; CYTARABINE; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE;

EID: 1842685192     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.034     Document Type: Article

References (26)

1. Burnett A.K., Goldstone A.H., Stevens R.M., Hann I.M., Rees J.K., Gray R.G.et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet. 351(9104):1998;700-708.
2. Weick J.K., Kopecky K.J., Appelbaum F.R., Head D.R., Kingsbury L.L., Balcerzak S.P.et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 88(8):1996;2841-2851.
3. Matthews J.P., Bishop J.F., Young G.A., Juneja S.K., Lowenthal R.M., Garson O.M.et al. Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia. Br. J. Haematol. 113(3):2001;727-736.
4. Boissel N., Cayuela J.M., Preudhomme C., Thomas X., Grardel N., Fund X.et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 16(9):2002;1699-1704.
5. Kobayashi H., Takemura Y., Ohnuma T. Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects. Cancer Chemother. Pharmacol. 31(1):1992;6-10.
6. Kobayashi H., Takemura Y., Holl J.F., Ohnuma T. Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect. Biochem. Pharmacol. 55(8):1998;1229-1234.
7. Takemura Y., Kobayashi H., Miyachi H., Hayashi K., Sekiguchi S., Ohnuma T. The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro. Cancer Chemother. Pharmacol. 27(6):1991;417-422.
8. Kuh H.J., Jang S.H., Wientjes M.G., Au J.L. Computational model of intracellular pharmacokinetics of paclitaxel. J. Pharmacol. Exp. Ther. 293(3):2000;761-770.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65(1/2):1983;55-63.
10. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139(2):1991;271-279.
11. Austin Doyle L., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22(47):2003;7340-7358.
12. Speth P.A., van Hoesel Q.G., Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharmacokinet. 15(1):1988;15-31.
13. Balis F.M., Holcenberg J.S., Poplack D.G., Ge J., Sather H.N., Murphy R.F.et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. Blood. 92(10):1998;3569-3577.
14. Fleming R.A., Capizzi R.L., Rosner G.L., Oliver L.K., Smith S.J., Schiffer C.A.et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer Chemother. Pharmacol. 36(5):1995;425-430.
15. Friedmann A.M., Weinstein H.J. The role of prognostic features in the treatment of childhood acute lymphoblastic leukemia. Oncologist. 5(4):2000;321-328.
16. Nguyen S., Leblanc T., Fenaux P., Witz F., Blaise D., Pigneux A.et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 99(10):2002;3517-3523.
17. Braess J., Pfortner J., Kern W., Hiddemann W., Schleyer E. Cytidine deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann. Hematol. 78(11):1999;514-520.
18. Mancini W.R. The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3′-amino-2′,3′-dideoxycytidine and cytosine arabinoside. Cancer Chemother. Pharmacol. 30(2):1992;139-144.
19. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57(7):1999;727-741.
20. Paul C., Liliemark J., Tidefelt U., Gahrton G., Peterson C. Pharmacokinetics of daunorubicin and doxorubicin in plasma and leukemic cells from patients with acute nonlymphoblastic leukemia. Ther. Drug Monit. 11(2):1989;140-148.
21. Tapiero H., Munck J.N., Fourcade A. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo. Drugs Exp. Clin. Res. 12(1-3):1986;257-264.
22. Frost B.M., Eksborg S., Bjork O., Abrahamsson J., Behrendtz M., Castor A.et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med. Pediatr. Oncol. 38(5):2002;329-337.
23. Stein A.S., O'Donnell M.R., Slovak M.L., Nademanee A., Dagis A., Schmidt G.M.et al. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia. 14(7):2000;1191-1196.
24. Daenen S., van Imhoff G.W., van den Berg E., de Kam P.J., Haaxma-Reiche H., Vellenga E.et al. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a 'pre-induction' course for rapid tumour reduction: preliminary results on 66 patients. Br. J. Haematol. 100(2):1998;273-282.
25. 9/l. J. Clin. Oncol. 5(7):1987;1015-1021.
26. Niemeyer C.M., Gelber R.D., Tarbell N.J., Donnelly M., Clavell L.A., Blattner S.R.et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood. 78(10):1991;2514-2519.